

References

I-239

1. Weiss JM, Csoszi T, Maglakelidze M, et al: Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial. *Ann Oncol*. 2019;30(10):1613-1621.
2. Daniel D, Kuchava V, Bondarenko I, et al: Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: a multicentre, randomised, double-blind, placebo-controlled phase II trial. *Int J Cancer*. 2021;148(10):2557-2570.
3. National Comprehensive Cancer Network (NCCN). NCCN Drugs and Biologics Compendium®. 2022. Trilaciclib.
4. Clinical Pharmacology™ Tampa FL: Gold Standard, Inc. Trilaciclib. 2022.
5. Micromedex® Solutions Compendia. 2022.
6. Trilaciclib In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated March 15, 2021.
7. Cosela (trilaciclib) for injection, for intravenous use [package insert]. G1 Therapeutics, Inc. Durham, NC. Revised 2/2021.